Table 3.
Clinical data for individuals with co-morbid autoimmune disorders.
| DS/MMS AI (n = 28) % (95% CI) |
DS/MMS Non-AI (n = 24)
% (95% CI) |
MMD AI (n = 13) % (95% CI) |
MMD Non-AI (n = 64)
% (95% CI) |
DS AI (n = 428) % (95% CI) |
DS Non-AI (n = 789)
% (95% CI) |
||
|---|---|---|---|---|---|---|---|
| Male sex | 50 (30, 69) | 38 (19, 59) | 31 (9, 61) | 44 (31, 57) | 47 (43, 52) | 48 (44, 54) | |
| Race/Ethnicity | |||||||
| Caucasian Hispanic Asian Black Other |
89 (72, 98) 39 (22, 59) 7 (1, 24) 4 (0, 18) 0 (–, –) |
79 (58, 93) 33 (16, 55) 13 (3, 32) 4 (0, 21) 4 (0, 21) |
54 (25, 81) 54 (25, 81) 31 (9, 61) 15 (2, 45) 0 (–, –) |
77 (64, 86) 38 (26, 50) 19 (10, 30) 3 (0, 11) 2 (0, 1) |
88 (84, 91) 36 (31, 40) 9 (7, 13) 3 (2, 5) 0 (–, –) |
86 (84, 89) 35 (32, 39) 9 (7, 12) 4 (3. 5) 1 (0, 2) |
|
| Age (median, IQR) | 14 (7.5–17) | 12 (8.25–17) | 15 (13–17) | 12.5 (6.5–17) | 11 (7–15) | 11 (7–15) | |
| TPO Antibodies | |||||||
| Positive Negative Not Tested |
75 (55, 89) 14 (4, 33) 11 (2, 28) |
25 (10, 47) 50 (29, 71) 25 (10, 47) |
8 (0, 36) 62 (32, 86) 31 (9, 61) |
13 (6, 23) 27 (16, 39) 61 (48, 73) |
22 (18, 26) 42 (38, 47) 36 (31, 40) |
2 (1, 3) 23 (20, 26) 75 (72, 78) |
|
| Anti-Tg Antibodies | |||||||
| Positive Negative Not Tested |
64 (44, 81) 25 (11, 45) 11 (2, 28) |
25 (10, 47) 50 (29, 71) 25 (10, 47) |
8 (0, 36) 62 (32, 86) 31 (9, 61) |
11 (5, 21) 28 (18, 41) 61 (48, 73) |
22 (18, 26) 42 (38, 47) 36 (31, 40) |
2 (1, 3) 23 (20, 26) 75 (72, 78) |
|
| GAD65 Antibodies | |||||||
| Positive Negative Not Tested |
39 (22, 59) 29 (13, 49) 32 (16, 52) |
8 (1, 27) 33 (16, 55) 58 (37, 78) |
8 (0, 36) 16 (2, 45) 77 (46, 95) |
5 (1, 13) 28 (18, 41) 67 (54, 78) |
5 (3, 7) 23 (19, 27) 72 (68, 76) |
0 (–, –) 14 (11, 16) 86 (83, 88) |
|
| MOYAMOYA CLINICAL DATA | |||||||
| Presenting with CVA | 71 (51, 87) | 71 (49, 87) | 46 (19, 75) | 72 (59, 82) | |||
| Collaterals Present | 71 (51(87) | 88 (68, 97) | 77 (46, 95) | 81 (70, 90) | |||
| Laterality | |||||||
| Bilateral Unilateral Left Right |
68 (48, 84) 32 (16, 52) 21 (8, 41) 11 (2, 28) |
79 (58, 93) 21 (7, 42) 13 (3, 32) 8 (3, 17) |
77 (46, 95) 23 (5, 54) 15 (2, 45) 8 (0, 36) |
80 (68, 89) 20 (11, 32) 13 (6, 23) 5 (38.5) |
|||
| Suzuki Grade (median, IQR) | 3.0 (2–4) | 3 (3–4) | 3 (2–4) | 3 (2.75–5) | |||
| Hemorrhage | 0 (–, –) | 0 (–, –) | 0 (–, –) | 5 (1, 13) | |||
| Aneurysm | 4 (0, 18) | 0 (–, –) | 0 (–, –) | 0 (–, –) | |||
| Posterior Circulation Involvement TPO positive |
18 (6, 37) 82 (63, 94) |
38 (19, 59) 63 (41, 81) |
15 (2, 45) 85 (55, 98) |
20 (11, 32) 80 (68, 89) |
|||
AI, Autoimmune disease; CVA, cerebrovascular accident; GAD, glutamic acid decarboxylase; IQR, interquartile range; NS, non-significant; TPO, thyroid peroxidase; Tg, thyroglobulin.